Meeting
2020 ASCO Virtual Scientific Program
A first-in-class ex vivo combination between cytokine-induced memory like (CIML) NK cells and a CD38 targeting antibody recruiting molecule (ARM) as a novel approach to target NK cells without cellular engineering for the treatment of multiple myeloma.
Authors
Luca Rastelli
Kleo Pharmaceuticals, New Haven, CT
Luca Rastelli , Maqbool Mohsin , Ann Marie Rossi , Enrique Alvarez Sotomayor , Lawrence Iben , Ada Vaill , Matthew Welsch , Rizwan Romee , Anna Bunin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for Plasma Cell Disorders
Citation
J Clin Oncol 38: 2020 (suppl; abstr 8523)
DOI
10.1200/JCO.2020.38.15_suppl.8523
Abstract #
8523
Poster Bd #
423
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Increased frequency of PD-1+CD57+Siglec-7- dysfunctional NK cells in patients with nonalcoholic fatty liver disease.
First Author: Yuzuru Sakamoto
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Formation of FcRγ-deficient NK cell subset associated with HCMV-reactivation in hematopoietic cell transplant recipients.
First Author: Jaewon Lee
Poster
2015 ASCO Annual Meeting
Pre-clinical translational studies of daratumumab in patients with myeloma or AL amyloidosis undergoing autologous hematopoietic stem cell transplantation (SCT).
First Author: Chakra Pani Chaulagain
Poster
2011 ASCO Annual Meeting
A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma.
First Author: N. M. Reddy